The United States Food and Drug Administration recently authorized 20 ZYN nicotine pouch products to carry a specific health claim: that switching from cigarettes to these pouches lowers the risk of mouth cancer, heart disease, lung cancer, stroke, and emphysema.
This is significant because the FDA is one of the world's strictest regulatory bodies. It doesn't approve health claims lightly. The agency spent months reviewing scientific evidence, consumer understanding, youth risk data, and public comments before authorizing this claim for these specific products.
Why did they approve it?
The FDA's reasoning was clear. The agency stated that adults who smoke deserve access to science-based information about relative risks so they can make informed choices. The decision was based on evidence showing that non-combustible nicotine products expose users to fewer harmful chemicals than cigarettes.
But here's what the FDA was careful to say: this is not safe. There is no safe tobacco or nicotine product. People who don't use nicotine shouldn't start. And quitting entirely remains the healthiest option.
This raises a straightforward question for tobacco policy globally: If a strict regulator like the FDA recognizes that different products carry different risks, shouldn't that recognition shape how countries approach regulation?
The Maldives has recently taken several tobacco control measures: a generational ban, a vape ban, expanded cessation services, and a five-year campaign for a tobacco-free society. These protect future generations. But the country has also made policy decisions about adult smokers—reducing cigarette duties, removing duties on cessation products like nicotine gum and patches.
Are these decisions grounded in evidence about what actually helps people reduce smoking? When the FDA approves claims based on scientific review, what is that signaling about how evidence should inform policy?
The FDA wasn't endorsing nicotine pouches. It was saying: when evidence shows products differ in risk, regulators should acknowledge that difference.
Are our own tobacco policies built on evidence about what works? When we make decisions about cigarettes, alternatives, and cessation support, are we considering what the evidence actually shows about how people reduce smoking?
